Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile – – LA-PDAC program represents large ...
- Additional podium presentation to provide updates from long-term evaluation of Padeliporfin VTP in intermediate-risk prostate cancer - TEL AVIV, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- ImPact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results